Faye Beverley McMillan

Dr. Faye Beverley McMillan

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2022 in Australian Journal of Rural Health
Verified
Journal Article
Open access
PDF file
Mark Lock (Ngiyampaa)Mark Lock (Ngiyampaa)
Mark Lock (Ngiyampaa)
FMFaye Beverley McMillan
Faye Beverley McMillan
BBBindi Bennett
Bindi Bennett
JMJodie Lea Martire
Jodie Lea Martire
DWDonald Warne
Donald Warne
RRRussell Roberts
Russell Roberts
Click on the article title to read more.

1 June 2021 in Clinical Therapeutics
Verified
Journal Article
Open access
GGGarima Gahlawat
Garima Gahlawat
WTWubshet Tesfaye
Wubshet Tesfaye
MBMary-Jessimine Bushell
Mary-Jessimine Bushell
SASolomon Abrha
Solomon Abrha
GPGregory M. Peterson
Gregory M. Peterson
TJThomas Jackson
Thomas Jackson
Impetigo affects approximately 162 million children worldwide at any given time. Lack of consensus on the most effective treatment strategy for impetigo and increasing antibiotic resistance continue to drive research into newer and alternative treatment options. We conducted a systematic review to assess the effectiveness of new treatments for impetigo in endemic and nonendemic settings. We searched PubMed, MEDLINE, CINAHL, Web of Science, and Embase via Scopus for studies that explored treatments for bullous, nonbullous, primary, and secondary impetigo published between August 1, 2011, and February 29, 2020. We also searched online trial registries and hand-searched the reference lists of the included studies. We used the revised Cochrane risk of bias (version 2.0) tool for randomized trials and the National Heart, Lung, and Blood Institute for nonrandomized uncontrolled studies to assess the risk of bias. We included 10 studies that involved 6651 participants and reported on 9 treatments in the final analysis. Most clinical trials targeted nonbullous impetigo or did not specify this. The risk of bias varied among the studies. In nonendemic settings, ozenoxacin 1% cream appeared to have the strongest evidence base compared with retapamulin and a new minocycline formulation. In endemic settings, oral co-trimoxazole and benzathine benzylpenicillin G injection were equally effective in the treatment of severe impetigo. Mass drug administration intervention emerged as a promising public health strategy to reduce the prevalence of impetigo in endemic settings. This review highlights the limited research into new drugs used for the treatment of impetigo in endemic and nonendemic settings. Limited recent evidence supports the use of topical ozenoxacin or retapamulin for impetigo treatment in nonendemic settings, whereas systemic antibiotics and the mass drug administration strategy have evidence for use in endemic settings. Given the troubling increase in resistance to existing treatments, there is a clear need to ensure the judicious use of antibiotics and to develop new treatments and alternative strategies; this is particularly important in endemic settings. PROSPERO identifier: CRD42020173042.

2 January 2017 in Digital Creativity
Verified
Journal Article
Closed access
YAYoko Akama
Yoko Akama
DEDebra Evans
Debra Evans
SKSeth Keen
Seth Keen
FMFaye Beverley McMillan
Faye Beverley McMillan
MMMark McMillan
Mark McMillan
PWPeter West
Peter West
The proliferation of digitally mediated DIY practices constitutes new modalities of political expression and participation, shaping how citizenship is enacted and performed. However, our paper begins by problematizing concepts of citizenship in media and communication contexts that only speaks to identity-formation. For Indigenous Australians, citizenship does not need to be asserted or constructed—they are sovereign and they have never ceded their land, rights or identity. Pursuing this argument, we share insights of various digital and creative scaffolds that are being designed with Wiradjuri people as continuous ‘infrastructuring’ to express and practice Wiradjuri sovereignty. This exploration is enabling a political identity to form and creating multiple places to be Wiradjuri together. We also discuss how designing digital and creative scaffolds can be considered as a meeting place of sovereigns, to attend to a consciousness that non-Indigenous people are also practising their own sovereignty in relation to respecting Indigenous sovereignty/ies.

31 May 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
TJThomas Jackson
Thomas Jackson
RDRachel Davey
Rachel Davey
GPGregory M Peterson
Gregory M Peterson
CCChristine Carson
Christine Carson
SWShelley F Walton
Shelley F Walton
KBKavya E Baby
Kavya E Baby
Introduction In remote Aboriginal communities in Australia, scabies affects 7 out of 10 children before their first birthday. This is more than six times the rate seen in the rest of the developed world. Scabies infestation is frequently complicated by bacterial infection, leading to the development of skin sores and other more serious consequences, such as septicaemia and chronic heart and kidney diseases. Tea tree oil (TTO) has been used as an antimicrobial agent for several decades with proven clinical efficacy. Preclinical investigations have demonstrated superior scabicidal properties of TTO compared with widely used scabicidal agents, such as permethrin 5% cream and ivermectin. However, current data are insufficient to warrant a broad recommendation for its use for the management of scabies because previous studies were small or limited to in vitro observations. Methods and analysis A pragmatic first trial will examine the clinical efficacy of a simple and low-cost TTO treatment against paediatric scabies and the prevention of associated secondary bacterial infections, with 1:1 randomisation of 200 participants (Aboriginal children, aged 5–16 years and living in remote Australia) into active control (permethrin 5% cream) and treatment (5% TTO gel) groups. The primary outcome for the study is clinical cure (complete resolution). Secondary outcome measures will include relief of symptoms, recurrence rate, adverse effects, adherence to treatment regimen and patient acceptability. Ethics and dissemination The project has received approvals from the University of Canberra Human Research Ethics Committee (HREC 16-133), Wurli-Wurlinjang Health Service Indigenous subcommittee and the Aboriginal Medical Services Alliance Northern Territory reference group. The results of this study will be published in core scientific publications, with extensive knowledge exchange activities with non-academic audiences throughout the duration of the project. Trial registration ACTRN12617000902392; Pre-results.

1 May 2010 in Dementia
Verified
Journal Article
Open access
FMFaye Beverley McMillan
Faye Beverley McMillan
DKDavid Kampers
David Kampers
VTVictoria Traynor
Victoria Traynor
JDJan Dewing
Jan Dewing

20 October 2021 in Australian Journal of Rural Health
Verified
Journal Article
Open access
PDF file
RSRuth Stewart
Ruth Stewart
FMFaye Beverley McMillan
Faye Beverley McMillan
Click on the article title to read more.